Article: Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleEvidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
AuthorsSeto, WK
Tanaka, Y
Wong, DKH
Lai, CL
Shinkai, N
Yuen, JCH
Tong, T
Fung, J
Hung, IFN
Yuen, MF
KeywordsHBcrAg
HBsAg
Linearized HBsAg
Seroclearance
Serology
Issue Date2013
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
CitationHepatology International, 2013, v. 7 n. 1, p. 98-105 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-012-9354-7
AbstractBackground: Possible serologic activity after hepatitis B surface antigen (HBsAg) seroclearance documented by conventional assays in chronic hepatitis B (CHB) has not been thoroughly investigated. Methods: We determined the levels of serum hepatitis B virus (HBV) DNA, hepatitis B core-related antigen (HBcrAg), and linearized HBsAg (CLEIA prototype) in 329 CHB patients (72.0% male) after HBsAg seroclearance was documented by a conventional HBsAg assay. Results: The median interval between presentation and HBsAg seroclearance was 69.4 months. The median age at HBsAg seroclearance was 50 years. Assays for serum HBV DNA, HBcrAg, and linearized HBsAg were performed at a median time interval of 11.2 months after HBsAg loss. Linearized HBsAg and HBcrAg were detectable in 85 (25.8%) and 69 (21%) patients, respectively, and one or both serologic markers were detectable in 133 patients (40.4%). Serum HBV DNA was detectable in only 7 patients (2.1%). There was no correlation between linearized HBsAg and HBcrAg levels (r = 0.095, p = 0.924). The incidences of detectable linearized HBsAg and HBcrAg did not differ between patient samples taken at 6-12 and >12 months after HBsAg seroclearance (p = 0.146 and 0.079, respectively). Among patients with detectable serologic markers, median levels of linearized HBsAg (p = 0.581) and HBcrAg (p = 0.951) did not significantly change with time after HBsAg seroclearance. Conclusion: Using novel HBcrAg and linearized HBsAg assays, viral serologic activity after HBsAg seroclearance was demonstrated in more than 40% of CHB patients. These tests have potential applications in diagnosing and prognosticating CHB patients with HBsAg seroclearance. © 2012 Asian Pacific Association for the Study of the Liver.
ISSN1936-0533
2011 Impact Factor: 2.645
2011 SCImago Journal Rankings: 0.244
DOIhttp://dx.doi.org/10.1007/s12072-012-9354-7
DC Field
Value
dc.contributor.authorSeto, WK
dc.contributor.authorTanaka, Y
dc.contributor.authorWong, DKH
dc.contributor.authorLai, CL
dc.contributor.authorShinkai, N
dc.contributor.authorYuen, JCH
dc.contributor.authorTong, T
dc.contributor.authorFung, J
dc.contributor.authorHung, IFN
dc.contributor.authorYuen, MF
dc.date.accessioned2012-09-05T05:31:43Z
dc.date.available2012-09-05T05:31:43Z
dc.date.issued2013
dc.description.abstractBackground: Possible serologic activity after hepatitis B surface antigen (HBsAg) seroclearance documented by conventional assays in chronic hepatitis B (CHB) has not been thoroughly investigated. Methods: We determined the levels of serum hepatitis B virus (HBV) DNA, hepatitis B core-related antigen (HBcrAg), and linearized HBsAg (CLEIA prototype) in 329 CHB patients (72.0% male) after HBsAg seroclearance was documented by a conventional HBsAg assay. Results: The median interval between presentation and HBsAg seroclearance was 69.4 months. The median age at HBsAg seroclearance was 50 years. Assays for serum HBV DNA, HBcrAg, and linearized HBsAg were performed at a median time interval of 11.2 months after HBsAg loss. Linearized HBsAg and HBcrAg were detectable in 85 (25.8%) and 69 (21%) patients, respectively, and one or both serologic markers were detectable in 133 patients (40.4%). Serum HBV DNA was detectable in only 7 patients (2.1%). There was no correlation between linearized HBsAg and HBcrAg levels (r = 0.095, p = 0.924). The incidences of detectable linearized HBsAg and HBcrAg did not differ between patient samples taken at 6-12 and >12 months after HBsAg seroclearance (p = 0.146 and 0.079, respectively). Among patients with detectable serologic markers, median levels of linearized HBsAg (p = 0.581) and HBcrAg (p = 0.951) did not significantly change with time after HBsAg seroclearance. Conclusion: Using novel HBcrAg and linearized HBsAg assays, viral serologic activity after HBsAg seroclearance was demonstrated in more than 40% of CHB patients. These tests have potential applications in diagnosing and prognosticating CHB patients with HBsAg seroclearance. © 2012 Asian Pacific Association for the Study of the Liver.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationHepatology International, 2013, v. 7 n. 1, p. 98-105 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-012-9354-7
dc.identifier.citeulike10463261
dc.identifier.doihttp://dx.doi.org/10.1007/s12072-012-9354-7
dc.identifier.epage105
dc.identifier.issn1936-0533
2011 Impact Factor: 2.645
2011 SCImago Journal Rankings: 0.244
dc.identifier.scopuseid_2-s2.0-84875241425
dc.identifier.spage98
dc.identifier.urihttp://hdl.handle.net/10722/163465
dc.languageeng
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
dc.publisher.placeUnited States
dc.relation.ispartofHepatology International
dc.subjectHBcrAg
dc.subjectHBsAg
dc.subjectLinearized HBsAg
dc.subjectSeroclearance
dc.subjectSerology
dc.titleEvidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
dc.typeArticle
Author Affiliations
  1. Nagoya City University
  2. The University of Hong Kong